Pharmacokinetic Study With Colchicine in Healthy Volunteers

Status Completed

Clinical Trial Summary

Clinical Trial Description

This open label, single group, sequential dose study will compare the single dose pharmacokinetics of colchicine 0.6 mg given orally to colchicine pharmacokinetics after 10 days of a standard prophylactic dose (0.6 mg every 12 hours) in healthy volunteers. After a fast of at least 10 hours, fourteen healthy non-smoking, non-obese, non-pregnant volunteers will receive a single oral dose of colchicine 0.6 mg. Fasting will continue for 4 hours after the dose, at which time a standard meal will be served. Blood will be drawn from all participants at times sufficient to adequately define the single dose pharmacokinetics of colchicine and its 3 major metabolites, 2, 3 and 10 demethylcolchicine. Following a 14 day washout period, all participants will begin a 10 day regimen of colchicine 0.6 mg orally every 12 hours. On the morning of day 25, after a fast of at least 10 hours, all participants will receive their final dose of colchicine 0.6 mg. Again blood will be drawn at times sufficient to determine the pharmacokinetics of colchicine and its 3 major metabolites after chronic dosing. The pharmacokinetic parameters for each dosing situation will be derived and compared for relevant differences. Though not a specific goal of this study, all participants will be monitored for adverse events by observation and query during periods of confinement on days 1, 15 and 25, as well as by complete blood count (CBC) with differential and clinical chemistry, sitting and standing blood pressures, and heart rate and 12-lead electrocardiogram (EKG) before and after dosing, on days 1 and 25. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Pharmacokinetics

Clinical Trial Details

NCT number	NCT01017003
Study type	Interventional
Source	Mutual Pharmaceutical Company, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	September 2007
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04092725` - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects	Phase 1
Completed	`NCT04181008` - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers	Early Phase 1
Active, not recruiting	`NCT03258151` - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed	`NCT04406415` - Oral Nafamostat in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT05421312` - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip	Phase 4
Completed	`NCT02534753` - A Pharmacokinetics Study of Intravenous Ascorbic Acid	Phase 1
Completed	`NCT01976078` - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents	N/A
Completed	`NCT01682408` - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability	Phase 1
Completed	`NCT01636024` - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594	Phase 1
Completed	`NCT01214941` - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol	Phase 4
Completed	`NCT01208155` - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets	Phase 1
Completed	`NCT01415102` - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.	Phase 1
Completed	`NCT01260025` - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor	Phase 1
Completed	`NCT00747721` - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU	Phase 1
Completed	`NCT00856570` - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects	Phase 1
Completed	`NCT00983242` - Drug-Drug Interaction Between Colchicine and Verapamil ER	Phase 1
Completed	`NCT00730145` - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis	Phase 1
Completed	`NCT00746499` - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.	Phase 1
Completed	`NCT01276119` - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males	Phase 1
Completed	`NCT00984009` - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.